Biorestorative Therapies, Inc. · NASDAQ:BRTX
Biorestorative Therapies — Investor Presentation (June 2016)
17 slides from Biorestorative Therapies's investor presentation, Jun 2, 2016
Slide 1: Presentation
piorsstoniive PRESENTATION
Slide 2: Forward-looking statements
Statements in this presentation, including the information set forth as to the future financial or operating performance of BioRestorative Therapies, Inc. (the "Company"), that are not current or historical factual statements may constitute “forward looking’ information within the meaning of securit
Slide 3: BioRestorative Therapies company overview and core programs
BioRestorative Therapies, Inc. develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs relate to the treatment of disc/spine disease and metabolic disorders. ™ DISC/SPINE PROGRAM (brtxDISC™): « An advanced cell therapy to treat chron
Slide 4: Lower Back Pain is the Most Common, Disabling and Costly Problem
ower Back Pain is the Most Common, the Most Disabling, ana the Most Costly Musculoskeletal Problem Treated Viaasany> Protruding/ Bulging Disc Spinal Fusion Surgery INTRODUCING A NEW STANDARD OF CARE TO TREAT CHRONIC LUMBAR DISC DISEASE
Slide 5: Cell-Based Lumbar Disc Therapeutic
Cell-Based Lumb. sc Therapeutic Disc Therapy to Treat Chronic Lumbar Disc Disease (Protruding and Bulging Discs) @ BRTX-100 - Lead Cell Therapy Candidate Product Formulated from Autologous Cultured 4 Mesenchymal Stem Cells (or MSCs) Collected from the Patient's Bone Marrow @ Treatment is Intended fo
Slide 6: BRTX-100 treatment process
Collection and Shipment to BRT of Patient's Bone Marrow and Blood \ 4 Production of Thawing and i Injection of BRTX- : BRTX-100 100 into Patient's + Hypoxic Culturing Disc of MSCs Shipment of BRTX- 100 to Clinical Site/Physician
Slide 7: BRTX-100 Key Attributes
@ BRTX-100 Key Attributes: « Autologous * Contains Hypoxic (Low Oxygen) Cultured Mesenchymal Stem Cells ¢ High Cell Viability for Disc * Cryopreserved @ BRTX-100 Cell Based Therapy (2 step mechanism): ¢ Structural (Bio-Mechanical Properties) — Supply disc tissue-specific cells that replace lost or d
Slide 8: Physician-sponsored study of hypoxic cultured MSCs
@ A physician-sponsored, IRB-approved study investigated the effect of hypoxic cultured MSCs on disc protrusions (from 2008-2010) ™@ Safety observations: « No adverse events observed @ Efficacy observations: ¢ Reduction in pain — 67% of subjects (n=12)had = 30% improvement in pain score ¢ Improved f
Slide 9: Patient case and disc bulge reduction
42 yo Male needed epidural steroid injections multiple times annually for radiculopathy Large central, contained, broad based protrusion (L5-S1) 6 Years Conventional treatment « Narcotics « Epidural Steroids * Physical Therapy POST-TREATMENT 75% Reduction in disc bulge post treatment f 1 1 \ ‘. , 70
Slide 10: Planned randomized placebo-controlled study design
@ A prospective, double-blinded, placebo controlled, randomized study, n=62 « 12 patient dose escalation cohort with 10mm, 20mm and 40mm cell dose cohorts « 50 patient safety and efficacy cohort with maximum dose — Evaluate safety and preliminary efficacy of a single dose intradiscal injection of BR
Slide 11: Milestones Target Timeline
Milestones Target Timeline Animal Study Data 2Q 2016 Publish Animal Study Data 4Q 2016 Submit IND/IND Clearance 4Q 2016 Patient Enrollment 1Q 2017 Dose Escalation Cohort Data 3Q 2017 Primary End Point Efficacy Data 3Q 2018
Slide 12: ThermoStem metabolic program: brown adipose stem cells
= Pre-clinical allogeneic cell-basedtherapy to target obesity, diabetes and other metabolic disorders using brown adipose (fat) derived stem cells (BADSC) to generate brown adipose tissue (BAT) = BATisa specialized adipose tissue foundin the human body that plays a key role in the evolutionarily con
Slide 13: 2014 Publication in STEM CELLS
2014 Publication in STEM CELLS Volume 22. sry 2018 ‘STEM CELLS 572. Metabolically Active Human Brown Adipose Tissue-Derived Stem Cells Francisco J Silva, Dolly J Holt, Vanessa Vargas et al. 1s TAANSLAGLONAL MLDINE
Slide 14: Brown Fat Delivery Device
Brown Fat Delivery Device Encapsulation Device
Slide 15: Milestones Target Timeline
Milestones Target Timeline Identify Key Cell Line for Pre-Clinical Testing 3Q 2016 Develop Delivery System for BAT 3Q 2016 Initiate Pre-Clinical Testing in Animals 4Q 2016 Identify Target Indication 4Q 2016 Complete Pre-Clinical Testing in Animals 2Q 2017 Pre-IND filing with FDA 3Q 2017
Slide 16: Multiple Cell Therapy Programs
MULTIPLE CELL THERAPY PROGRAMS ™ DISC/SPINE PROGRAM (brtxDISC™): « An advanced cell therapy to treat chronic lumbar disc disease caused by protruding or bulging discs * Lead therapeutic product, “BRTX-100”, has been engineered to promote healing in damaged intervertebral discs ¢ IND submission targe
Slide 17: BioRestorative Therapies - biorestorative.com
plorestordtive OTCQB: BRTX * biorestorative.com
BioRestorative Therapies — Investor Presentation (June 2016) on 6ix